|1.||Schulz, Stefan: 8 articles (09/2015 - 12/2004)|
|2.||Hommann, Merten: 4 articles (09/2015 - 01/2012)|
|3.||Kaemmerer, Daniel: 4 articles (09/2015 - 01/2012)|
|4.||Kundra, Vikas: 4 articles (09/2009 - 03/2002)|
|5.||Schindler, M: 4 articles (01/2001 - 01/2000)|
|6.||Sänger, Jörg: 3 articles (09/2015 - 01/2012)|
|7.||Melmed, Shlomo: 3 articles (01/2015 - 06/2004)|
|8.||Spada, A: 3 articles (08/2014 - 08/2005)|
|9.||Coy, David H: 3 articles (08/2013 - 01/2012)|
|10.||Vranic, Mladen: 3 articles (08/2013 - 01/2012)|
04/01/2009 - "Treatment with SSTR2A may be effective for endocrine tumors. "
11/05/2015 - "Alteration of somatostatin receptor 2 expression in canine mammary gland tumor."
03/01/2015 - "SSTR2A and SSTR3 are more likely to be expressed in SDH-deficient PC/PGLs as compared with tumors demonstrating normal SDHB staining pattern. "
03/01/2015 - "SDH-deficient tumors were more likely to demonstrate moderate or strong staining for SSTR2A and SSTR3 when compared with SDH-sufficient tumors (91% versus 49% [P < .0001] and 50% versus 21% [P = .0008], respectively). "
01/01/2015 - "SSTR2A seems not to be overexpressed in GBM samples tested, neither on the cell surface of resident microglia or infiltrating macrophages, nor on the surface of tumor cells. "
|2.||Neoplasm Metastasis (Metastasis)
01/01/2015 - "SSTR expression was consistent between the primary skin tumour and the corresponding metastases for SSTR2A and SSTR5 in 3/7 and 6/7 cases, respectively. "
11/01/2010 - "Among the ten cases of lymph node metastasis, SSTR2a expression was markedly higher. "
02/01/2009 - "For somatostatin receptor type 2, the observed agreements were 91% (kappa=0.81), 69% (kappa=0.49) and 79% (kappa=0.68) in single, synchronous and metachronous liver metastases, respectively. "
02/20/2007 - "Detection of expression of SSTR2A, SSTR5 and EGFR might be helpful to evaluate lymph node metastasis, pathological stages and prognosis of NSCLC."
01/01/2006 - "Of 7 hepatic ECA metastases from pancreatic ECAs, 4 expressed SSTR-1, 6 expressed SSTR-2, and 5 expressed SSTR-3 and SSTR-5 each. "
11/01/2010 - "Immunohistochemical study of SSTR2a was performed on 95 prostate carcinoma cases, and the results showed expression of SSTR2a in 14 of the 95 cases (14.74%); the histological grade (Gleason) and capsular invasion of the prostate carcinoma were directly related to SSTR2a expression. "
11/01/2010 - "The purpose of this study is to detect SSTR2a in human prostate carcinomas and to elucidate the effects of SA on SSTR2a-positive prostate carcinoma cells to determine the potential of this drug as a new therapeutic method for advanced prostate carcinoma. "
06/15/2009 - "The purpose of this study was to evaluate the biodistribution and toxicity of Ad5.SSTR/TK.RGD, an infectivity-enhanced adenovirus expressing a therapeutic suicide gene and somatostatin receptor type 2 (for noninvasive assessment of gene transfer with nuclear imaging) in advance of a planned phase I clinical trial for recurrent ovarian carcinoma. "
03/01/2015 - "Methylation pattern is presented here for first time as a potential molecular marker of changes on SSTR2A and SHP-1(I) gene promoter related to breast and prostate carcinoma. "
03/01/2015 - "Association between methylation of SHP-1 isoform I and SSTR2A promoter regions with breast and prostate carcinoma development."
11/01/2003 - "Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study."
01/10/2010 - "Our data showed that: tuberous sclerosis 2 (TSC2) and phosphatase and tensin homolog (PTEN) were downregulated in most of the primary tumors, and their low expression was significantly associated with shorter disease-free and overall survival; somatostatin receptor 2 (SSTR2) was absent or very low in insulinomas compared with nonfunctioning tumors; and expression of fibroblast growth factor 13 (FGF13) gene was significantly associated with the occurrence of liver metastasis and shorter disease-free survival. "
12/01/1995 - "The patients (6 men and 5 women, age 28-68, mean 45 years) were affected by a variety of tumors which supposedly express somatostatin receptors: 2 meningotheliomatous meningiomas post-surgery; 2 glucagonomas with liver metastases observed on CT; 2 patients with suspicion of insulinoma; 2 carcinoids, one after surgery; 1 ectopic-ACTH Cushing's syndrome; 1 intracranial germinoma, post-surgery, in whom the study was requested to evaluate a doubtful finding of pulmonary metastatic lesion on CT; and 1 acromegaly showing, on MRI, and empty sella turcica occupied by and extraflexion of the lower portion of the chiasmatic cisterna without signs of adenoma and the sphenoidal sinus occupied by tissue wit inflammmatory characteristics. "
|5.||Hypoglycemia (Reactive Hypoglycemia)
07/01/2013 - "The purpose of this study was to determine whether SSTR2 antagonism (SSTR2a) ameliorates hypoglycemia in response to overinsulinization in diabetic rats previously exposed to recurrent hypoglycemia. "
07/01/2013 - "On Expt-D1, all rats developed hypoglycemia by ∼90 min, while on Expt-D2, hypoglycemia was attenuated with SSTR2a treatment (nadir = 3.7 ± 0.3 vs. 2.7 ± 0.3 mmol/L in SSTR2a and controls, P < 0.01). "
07/01/2013 - "Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats."
01/01/2012 - "To evaluate the effect of the SSTR2a in the absence of hypoglycemia, rats underwent a 4-h infusion of saline (Ctrl:N, Ctrl:D) or SSTR2a (Ctrl:D+SSTR2a) only. "
07/01/2013 - "Glucagon response to hypoglycemia on Expt-D2 deteriorated by 20-fold in the placebo group (P < 0.001) but improved in the SSTR2a group (threefold increase in area under the curve [AUC], P < 0.001). "
|1.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|5.||fibroblast growth factor 13
|7.||Somatostatin Receptors (Somatostatin Receptor)
|8.||Epidermal Growth Factor Receptor (EGF Receptor)
|9.||Messenger RNA (mRNA)
|1.||Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
|2.||Heterologous Transplantation (Xenotransplantation)